Abstracts tagged "Anti-CCP"

Abstract Number: 0158 • ACR Convergence 2024
Rheumatoid Arthritis Testing Patterns by Physicians and Advanced Practice Providers from a National Commercial Laboratory, 2014 – 2023
Karis Lee¹, Min Kyung Lee², David Alfego³, Kristen Clark⁴ and Stanley Naides⁵, ¹Labcorp, Orlando, FL, ²Labcorp, San Diego, CA, ³Labcorp, Carlsbad, CA, ⁴Labcorp, Raleigh, NC, ⁵Labcorp, Dana Point, CA
Background/Purpose: With the commercialization of new diagnostic and monitoring tests for rheumatoid arthritis (RA) and an increasing number of advanced practice providers (APPs) in the…
Abstract Number: 0488 • ACR Convergence 2024
Association of Anti-CarP Levels with Clinical Activity and Serological Profile in Rheumatoid Arthritis
Pablo Martínez Calabuig¹, Elena Grau García², Samuel Leal Rodriguez², Ernesto Tovar Sugrañes³, José Ivorra-Cortés⁴, Carmen Riesco Barcena³, Anderson Huaylla Quispe³, Laura Mas Sánchez⁵, Pablo Muñoz Martínez⁶, Daniel Ramos Castro³, Alba Torrat noves⁷, Iago Alcantara Alvarez⁸, Belén Villanueva Mañés⁸, Miguel Simeo Vinaixa⁸, Andrés Pérez Hurtado³ and Jose A Román-Ivorra⁹, ¹HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, ²HUP La Fe, Valencia, Spain, ³Rheumatology Department. HUP La Fe, Valencia, Spain, ⁴Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, ⁵Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, ⁶Hospital Universitario y Politècnico La Fe, Sagunto, Spain, ⁷Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, ⁸Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁹Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease where the presence of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (antiCCP) has been associated to…
Abstract Number: 1363 • ACR Convergence 2023
Plasma Neutrophil Extracellular Trap Remnant Levels Are Lower in Premenopausal Healthy Women Using Oral Contraceptive Pills
Background/Purpose: Women develop RA 3 times more often than men, and several risk factors for RA are female specific. Prior studies demonstrate an association between…
Abstract Number: 1741 • ACR Convergence 2023
The Occurrence and Phenotype of Autoreactive T Cells in the At-Risk Phase of Rheumatoid Arthritis
Sara Turcinov¹, Charlotte de Vries², Ravi Kumar Sharma², Christina Gerstner², Bruno Raposo², Anatoly Dubnovitsky², William Kwok³, Karine Chemin², Vivianne Malmström⁴ and Aase Hensvold⁵, ¹Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet. Theme of Inflammation and Ageing, Medical Unit Gastro, Derma, Rheuma, Karolinska University Hospital, Stockholm, Sweden, ²Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet. Center for Rheumatology, Academic Specialist Center, Stockholm, Sweden
Background/Purpose: CD4+ T cells recognizing citrullinated epitopes are present in peripheral blood of anti-citrulline protein antibody (ACPA) positive rheumatoid arthritis (RA) patients at time of…
Abstract Number: 1746 • ACR Convergence 2023
Smoking as a Risk Factor for Rheumatoid Arthritis: Exclusive Association with IgA Autoantibodies
Tineke van Wesemael¹, Anna Svärd², Annemarie Dorjee¹, Thomas Huizinga¹, René Toes¹ and Diane van der Woude¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Centre for Clinical Research Dalarna, Uppsala, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is characterized by autoantibodies to anti-modified protein autoantibodies (AMPAs) like anti-citrullinated protein antibodies (ACPA) and anti-acetylated protein antibodies (AAPA). Smoking is…
Abstract Number: 1763 • ACR Convergence 2023
Asthma Severity Is Associated Increased Serum Anti-cyclic Antibody Level at Baseline and in Increase During Longitudinal Follow-up
Drayton Rorah¹, Linh Ngo², Mario Castro², Kristen Demoruelle³ and Scott Matson⁴, ¹University of Kansas Medical Center, Kansas City, KS, ²University of Kansas School of Medicine, Kansas City, KS, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴University of Kansas School of Medicine, Kansas City, MO
Background/Purpose: The lung airways have been implicated in the pathogenesis of RA. RA-associated autoantibodies, including anti-cyclic citrullinated peptide (anti-CCP) antibodies are found to be generated…
Abstract Number: 1764 • ACR Convergence 2023
Antibody Responses to Citrullinated Type II Collagen and Vimentin Modified with Malondialdehyde-Acetaldehyde Differ in Rheumatoid Arthritis and Rheumatoid Arthritis-Interstitial Lung Disease
Breanna Butler¹, Jill Poole¹, Michael Duryee¹, Nozima Aripova¹, Carlos Hunter¹, Bridget Kramer¹, James O'Dell¹, Geoffrey Thiele¹, Bryant England¹ and Ted R Mikuls², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Interstitial lung disease (ILD) causes significant complications and mortality in patients with rheumatoid arthritis (RA). We have previously shown that patients with RA-ILD had…
Abstract Number: 1768 • ACR Convergence 2023
The Dynamics of the Gut Microbiome in Rheumatoid Arthritis Susceptibility: A Cross-Sectional and Longitudinal Observational Study
Christopher Rooney¹, Ian Jeffery², Kulveer Mankia³, Mark Wilcox¹ and Paul Emery⁴, ¹University of Leeds, Leeds, United Kingdom, ²4D Pharma plc, Cork, Ireland, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Multiple compositional shifts of gut microbiota have been identified within the rheumatoid arthritis (RA) disease continuum, encompassing both established RA and at-risk individuals (including…
Abstract Number: 2121 • ACR Convergence 2023
Clinical Significance of Negative Seroconversion of Anti-CCP and Anti-Mutated Citrullinated Vimentin Antibodies in Patients with Rheumatoid Arthritis
Takao Fujii, Katsunori Tanaka, Ryo Matsumiya, Kayoko Tabata and Shigeru Iwata, Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan
Background/Purpose: Anti-cyclic citrullinated peptide antibody (anti-CCP Ab) positivity is closely associated with bone destruction in rheumatoid arthritis (RA) patients, but the correlation between the Ab…
Abstract Number: 2141 • ACR Convergence 2023
Glucocorticoid Treatment in Early Rheumatoid Arthritis Is Associated with Increased Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Levels: A Post-hoc Analysis of a Randomized Controlled Trial (NORD-STAR)
Kristina Lend¹, Jos W.R. Twisk², Nupur Kumar³, John Lampa⁴, Anna Rudin⁵, Merete Hetland⁶, Till Uhlig⁷, Dan Nordstrom⁸, Mikkel Østergaard⁹, Marte Schrumpf Heiberg¹⁰, Espen A Haavardsholm¹⁰, Bjorn Gudbjornsson¹¹, Tuulikki Sokka-Isler¹², Gerdur Maria Grondal¹³, Kim Hørslev-Petersen¹⁴, Michael Nurmohamed², Ronald van Vollenhoven² and Johan Frostegård³, ¹Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³Karolinska Institutet, Stockholm, Sweden, ⁴Stockholm County, Hãsselby, Sweden, ⁵Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁶Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁷Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁸Helsinki University Hospital, Helsinki, Finland, ⁹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ¹⁰Diakonhjemmet Hospital, Oslo, Norway, ¹¹Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ¹²Jyvaskyla Central Hospital, Jyväskylä, Finland, ¹³Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ¹⁴University of Southern Denmark, Odense, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is associated with an elevated risk for developing atherosclerotic cardiovascular disease (CVD). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key…
Abstract Number: 2431 • ACR Convergence 2023
Integrated Single Cell Multi-omics Analysis in At-Risk for Future Rheumatoid Arthritis (RA) and Early RA Reveals Shared Transcription Factor Profiles in Multiple Cell Lineages
Cong Liu¹, David Boyle¹, Adam Savage², Marie Feser³, Kristen Demoruelle³, kristine Kuhn⁴, Michael Holer³, kevin Deane³, Palak Genge², Morgan Weiss², Veronica Hernandez², Julian Reading², Jane Buckner⁵, Tom Bumol², Mark Gillespie², Peter Skene², Wei Wang⁶ and Gary Firestein¹, ¹University of California San Diego, San Diego, CA, ²Allen Institute for Immunology, Seattle, WA, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴University of Colorado School of Medicine, Aurora, CO, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶University of California San Diego, La Jolla, CA
Background/Purpose: Identifying molecular signatures associated with anti-citrullinated protein antibody (ACPA) positive individuals who are 'at-risk' for future RA (At-Risk) and early RA (ERA) requires comprehensive…
Abstract Number: 0081 • ACR Convergence 2023
RA Disease Activity Influence the Frequency and Phenotype of Citrulline Reactive CD4 T Cells in DRB1*04:04 ACPA+ RA Patients
Cliff Rims¹, Anne Hocking¹, Sylvia Posso¹, Bernard Ng², Jeffrey Carlin³, Jane Buckner⁴ and Eddie James⁴, ¹Benaroya Research Institute, Seattle, WA, ²Veteran Affairs, Seattle, WA, ³Virginia Mason Medical Center, Seattle, WA, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA
Background/Purpose: The presence of ACPA in RA signifies an immune response toward citrullinated auto-antigens in disease pathogenesis and persistence. RA is a T cell mediated…
Abstract Number: 2582 • ACR Convergence 2023
Expansion of Circulating HLA-DR+ Peripheral Helper T Cells and CXCR5−CD38+ Mature Naïve B Cells in ACPA-positive Individuals At-risk for and with Classified RA
Hideto Takada¹, Kristen Demoruelle¹, Kevin Deane¹, Shohei Nakamura², Yasuhiro Katsumata³, Katsunori Ikari², Jane Buckner⁴, William H. Robinson⁵, Jennifer Seifert¹, Marie Feser¹, LauraKay Moss¹, Jill Norri⁶, Masayoshi Harigai³, Elena Hsieh¹, Michael Holer¹ and Yuko Okamoto², ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ³Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Stanford University, Palo Alto, CA, ⁶Colorado School of Public Health, Denver, CO

Background/Purpose: Production of ACPA following T and B cell interactions is a hallmark of ACPA+ RA. Recently identified peripheral helper T (Tph) cells have B…
Abstract Number: 0281 • ACR Convergence 2023
Is There a Decreased Risk of Developing CF Arthropathy in CF Patients Undergoing Treatment That Targets the F508del Mutation?
Kristin Schmiedeberg¹, Anna-Lena Walter¹, Lukas Joos¹, Martin Brutsche¹, Johannes von Kempis² and Andrea Rubbert-Roth¹, ¹Cantonal Hospital St. Gallen, St. Gallen, Switzerland, ²Kantonsspital St. Gallen, Division of rheumatology and immunology, St. Gallen, Switzerland
Background/Purpose: Cystic fibrosis (CF) is characterized by mutations within the CFTR (cystic fibrosis transmembrane conductance regulator) gene that result in a defect of the chloride…
Abstract Number: 0389 • ACR Convergence 2023
The Role of anti-CCP3 Antibodies in anti-CCP2 Antibody Negative Patients with Musculoskeletal Symptoms
Andrea Di Matteo¹, Kulveer Mankia², Leticia Garcia-Montoya², Jacqueline Nam², Sana sharrack³, Michael Mahler⁴ and Paul Emery³, ¹Polytechnic University of Marche, Jesi, Italy, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁴Werfen, San Diego, CA
Background/Purpose: To investigate, in primary care, whether testing anti-CCP3 antibodies in anti-CCP2 negative individuals with musculoskeletal (MSK) symptoms, improved the prediction of inflammatory arthritis (IA)/rheumatoid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].